Immunogenic decapeptide as a therapeutic for melanoma

JOINT EVENT ON 15^th International PHARMACEUTICAL MICROBIOLOGY AND BIOTECHNOLOGY CONFERENCE & 10^th Annual MEDICAL MICROBIOLOGY SUMMIT & EXPO

June 21-23, 2017 London, UK

Navnit Kumar Mishra

M M University, India

Posters & Accepted Abstracts: J Med Microb Diagn

Abstract :

Melanoma is a cancer associated with melanin forming cells known as melanocytes of epidermis. The malignant melanoma is increasing at alarming rate worldwide because of ozone layer depletion. Hence, there is an urgent need of the scientists from multidisciplinary areas to targeting the immunological receptors coupled with melanoma. In the present study a mutated decapeptide with ELAGIGILTV epitope has been taken from the melanoma antigen recognized by Programmed Death Receptor (PD-1) of the T-lymphocytes. In general the T-lymphocytes recognize the tumor cells and destroy them. However, the cancer cells protect themselves by Programmed Death Ligand-1 (PD-L-1) present on their surface which interacts to Programmed Death Receptor of the T-lymphocyte by this interaction they overcome the immuno surveillance mechanism. The proposed novel immunogenic decapeptide can block PD-1 receptors of the T lymphocytes and prevent the PD-L-1 binding as well. Lymphocytes once freed from their blindness by the peptide, regain their defense potential by recognizing and destroying cancer cells. Targeting this mechanism of interaction through epitope may act as a therapeutic for the melanoma. Molecular dynamics and molecular docking were the techniques applied to explore the physiochemical properties associated with immunogenicity of the epitope to the receptors. Furthermore this immunogenic epitope can be developed as a vaccine for cancer treatment. Moreover, the potency of bioactive nanoparticle in nanomedicine is well known. Therefore engineering this epitope with bioactive nanoparticle adjuvant could substantially improve the efficacy of the designed vaccine.

Biography :

Email: navnitchem@yahoo.com